Journal List > Endocrinol Metab > v.25(2) > 1085819

TOOLS
Ahn: Letter: Comparison of the Efficacy of Octreotide Long-acting Repeatable and Lanreotide Autogel in Acromegalic Patients (J Korean Endocr Soc 25:37-45, 2010)
Letter
Endocrinology and Metabolism

Endocrinology and Metabolism 2010; 25(2): 157-158.

Published online: 30 June 2010

DOI: https://doi.org/10.3803/EnM.2010.25.2.157

Letter: Comparison of the Efficacy of Octreotide Long-acting Repeatable and Lanreotide Autogel in Acromegalic Patients (J Korean Endocr Soc 25:37-45, 2010)

Yu-Bae Ahn

Department of Internal Medicine, The Catholic University of Korea, College of Medicine, Seoul, Korea.

Copyright © 2010 Korean Endocrine Society

References

1. Mercado M, Borges F, Bouterfa H, Chang TC, Chervin A, Farrall AJ, Patocs A, Petersenn S, Podoba J, Safari M, Wardlaw J. SMS995B2401 Study Group. A prospective multicentre study to investigate the efficacy safety and tolerability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly. Clin Endocrinol (Oxf). 2007. 66:859–868.
2. Kim JY, Jee JH, Yoon CH, Chung YJ, Lee BY, Cho GY, Kim SY, Chung JH, Min YK, Lee MS, Lee MK, Kim KW. Efficacy of octreotide LAR in acromegalic patients. J Korean Soc Endocrinol. 2005. 20:344–352.
3. Colao A, Pivonello R, Auriemma RS, Briganti F, Galdiero M, Tortora F, Caranci F, Cirillo S, Lombardi G. Predictors of tumor shrinkage after primary therapy with somatostatin analogs in acromegaly: a prospective study in 99 patients. J Clin Endocrinol Metab. 2006. 91:2112–2118.
4. Andries M, Glintborg D, Kvistborg A, Hagen C, Andersen M. A 12-month randomized crossover study on the effects of lanreotide Autogel and octreotide long-acting repeatable on GH and IGF-l in patients with acromegaly. Clin Endocrinol (Oxf). 2008. 68:473–480.
TOOLS
Similar articles